Efficacy of Retreatments With Intravitreal Bevacizumab

Age Related Macular Degeneration Clinical Trial

Official title:

Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00406744
• Other study ID #: APEC-0012
• Status: Terminated
• Phase: Phase 3
• Start date: May 2006
• Est. completion date: November 2006

Study information

• Verified date: May 2024
• Source: Asociación para Evitar la Ceguera en México
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: November 2006
• Est. primary completion date: May 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 95 Years

Eligibility

Inclusion Criteria:

• * Any visual acuity

• OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.

• Active angiogram leakage

Exclusion Criteria:

• * Basal Inflammatory disease

• Endoftalmitis history

• Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• Choroidal Neovascularization
• Macular Degeneration
• Neovascularization, Pathologic

Intervention

Drug:
• Intravitreal injection of Bevacizumab

Locations

Country	Name	City	State
Mexico	Asociacion para Evitar la Ceguera en Mexico	Mexico DF	DF

Sponsors (1)

Lead Sponsor	Collaborator
Asociación para Evitar la Ceguera en México

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram